Drug Profile
AZM 475271
Alternative Names: AZM-475271; M475271Latest Information Update: 17 Aug 2015
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antineoplastics
- Mechanism of Action Src-Family kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Haematological malignancies; Solid tumours
Most Recent Events
- 29 Oct 2008 Phase-I clinical trials in Solid tumours in USA (PO)
- 29 Oct 2008 Phase-II clinical trials in Haematological malignancies in USA (PO)